Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Aspirin.
- Who it may be relevant to
- Registry conditions: Venous Thromboembolism. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.
Overview
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
Interventions
- Drug Aspirin
Non-enteric coated 81 mg Aspirin tablet.
Primary outcome measures
- Incidence of symptomatic thromboembolic events [Time frame: 90 days]
Secondary outcome measures (1)
- Incidence of specific adverse events [Time frame: 90 days]
Eligibility criteria
Inclusion criteria
- > 18 years of age
- Planning to undergo a primary total hip or knee arthroplasty
Exclusion criteria
- High risk patients for VTE as defined by:
- History of venous thromboembolism
- Active malignancy
- Known pro thrombotic condition
- BMI > 40
- Patients requiring anticoagulation for pre-existing conditions
- Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
- Patients not fluent in the language of the informed consent form
- Prisoners
- Pregnancy
- Reported to have mental illness or belonging to a vulnerable population
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- University of Miami Hospital — Miami
Identifiers
NCT: NCT04295486 · 20190973